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Abstract
Background: Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system in which
autoreactive myelin-specific T cells cause extensive tissue damage, resulting in neurological deficits. In the disease process, T
cells are primed in the periphery by antigen presenting dendritic cells (DCs). DCs are considered to be crucial regulators of
specific immune responses and molecules or proteins that regulate DC function are therefore under extensive investigation.
We here investigated the potential immunomodulatory capacity of the ATP binding cassette transporter P-glycoprotein (P-
gp). P-gp generally drives cellular efflux of a variety of compounds and is thought to be involved in excretion of
inflammatory agents from immune cells, like DCs. So far, the immunomodulatory role of these ABC transporters is unknown.
Methods and Findings: Here we demonstrate that P-gp acts as a key modulator of adaptive immunity during an in vivo
model for neuroinflammation. The function of the DC is severely impaired in P-gp knockout mice (Mdr1a/1b2/2), since
both DC maturation and T cell stimulatory capacity is significantly decreased. Consequently, Mdr1a/1b 2/2 mice develop
decreased clinical signs of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis.
Reduced clinical signs coincided with impaired T cell responses and T cell-specific brain inflammation. We here describe the
underlying molecular mechanism and demonstrate that P-gp is crucial for the secretion of pro-inflammatory cytokines such
as TNF-a and IFN-c. Importantly, the defect in DC function can be restored by exogenous addition of these cytokines.
Conclusions: Our data demonstrate that P-gp downmodulates DC function through the regulation of pro-inflammatory
cytokine secretion, resulting in an impaired immune response. Taken together, our work highlights a new physiological role
for P-gp as an immunomodulatory molecule and reveals a possible new target for immunotherapy.
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Introduction
Multiple sclerosis (MS) is the most common chronic inflamma-
tory disease of the central nervous system (CNS), characterized by
the presence of demyelinated lesions throughout the brain [1–4].
Experimental autoimmune encephalomyelitis (EAE) is a widely
accepted animal model for MS, sharing its clinical, immunological
and pathological characteristics [5]. The mechanisms of CNS
inflammation in MS and EAE involve generation of autoreactive,
myelin specific T helper (Th) cells in the peripheral lymphoid
organs, which subsequently enter the brain, initiate an immune
response and eventually cause destruction of myelin sheaths and
axonal loss [6]. Antigen-presenting cells like dendritic cells (DCs) are
important regulators of immune responses by presenting their
captured antigens to specific T cells [7]. In general, the maturation
status of DCs is a key determinant of how the immune response will
evolve [8,9]. Molecules or proteins that regulate DC maturation
and thereby control immune responses are under extensive
investigation, since this may provide tools for immune modulation.
One possible candidate for immunomodulation is P-glycoprotein
(P-gp; ABCB1), a well-known multi-drug resistance (MDR) efflux
pump, which transports a variety of substrates and drugs through
the membrane against a concentration gradient at the cost of ATP
hydrolysis [10,11]. P-gp was originally discovered as a prototypic
transporter involved in MDR of tumor cells [12], and was the first
drug efflux transporter to be detected on blood-brain barrier
endothelial cells [13]. P-gp is also expressed on a variety of immune
cells like monocytes, DCs, T and B cells [14] and is involved in the
efflux of inflammatory molecules such as steroids, prostaglandins
and cytokines [14–19], suggesting a function in immunomodula-
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tion. A limited number of studies have implied that P-gp can
modulate immune responses by regulating the emigration of
Langerhans cells to lymphoid organs [20] and APC maturation in
vitro via IL-12 secretion [21], but in vivo relevance is lacking.
Despite the reports suggesting immune-related functions of P-gp,
data on how P-gp exerts its action during immune responses remains
unknown. Therefore, the goal of our study was to investigate the
potential immunomodulatory role of P-gp in vivo. We here
demonstrate that DCs from P-gp knockout mice (Mdr1a/1b2/2,
[22]) are severely impaired in their maturation and T cell stimulatory
capacity. Consequently, Mdr1a/1b2/2 mice displayed reduced
clinical signs of EAE, which coincided with decreased inflammation
in the brain and an overall reduced T cell response. Taken together,
our findings highlight a novel immunomodulatory role for P-gp,
which may open new therapeutic avenues to interfere in the
pathogenesis of (auto)immune-related or inflammatory diseases.
Results
Mdr1a/1b 2/2 Mice Have Reduced Clinical Signs of EAE
EAE was induced in Mdr1a/1b2/2 and wild-type mice using
recombinant myelin oligodendrocyte glycoprotein (rMOG). Nota-
bly, Mdr1a/1b 2/2 mice showed significantly reduced clinical
signs of disease (*p,0.05) compared to wild-type animals during the
acute (day 15) and progressive (day 29) phase of disease (Figure 1a,
Table 1). Moreover, the total EAE score per animal was
significantly lower in Mdr1a/1b2/2 mice compared to wild-type
mice (Figure 1b). The observed differences in clinical signs were
associated with decreased demyelination in the brain of Mdr1a/
1b2/2 EAE animals (Figure S1). Decreased demyelination in
Mdr1a/1b2/2 animals coincided with diminished brain inflam-
mation as determined by the reduced numbers of infiltrated
macrophages in EAE lesions during the acute (Figure 2a,b) and
progressive (Figure 2e,f) phase of disease (see Table S3 for a detailed
overview). Notably, almost no CD3+ T cell infiltrates were observed
in Mdr1a/1b 2/2 EAE lesions during the acute (Figure 2c,d) and
progressive (Figure 2g,h) phase of disease (Table S3), suggesting that
the immune response and in particular the specific T cell response is
selectively affected in Mdr1a/1b 2/2 mice during EAE.
Reduced Th1 and Th2 Response in Mdr1a/1b2/2 Mice
during EAE
To determine whether T cell responses to rMOG were reduced
in Mdr1a/1b2/2 mice, we compared the proliferative capacity
and cytokine secretion of lymph node cells from Mdr1a/1b2/2
and wild-type animals at different time points of EAE. Interest-
ingly, lymph node cells from rMOG-immunized Mdr1a/1b2/2
mice showed significantly impaired MOG specific T cell
proliferation during the acute and progressive phase of disease
compared to wild-type animals (Figure 3a,b). Furthermore, MOG
specific secretion of Th1 cytokines IFN-c and TNF-a (Figure 3c–f)
and Th2 cytokines IL-10 and IL-5 (Figure 3g–j) by lymph node
cells was significantly decreased in rMOG-immunized Mdr1a/
1b2/2 mice compared to wild-type animals, whereas no changes
were observed in the secretion of the Th17 cytokine IL-17 (data
not shown). These results demonstrate a decreased Th1 and Th2
response in Mdr1a/1b2/2 mice compared to wild-type animals
upon immunisation with rMOG.
P-gp Regulates Inflammatory Cytokine Extrusion but Not
Polyclonal T Cell Activation
Reduced brain infiltration of CD3+ T cells in Mdr1a/1b2/2
EAE lesions (Figure 2) and a reduced T cell response to rMOG in
Mdr1a/1b2/2 mice suggests that the activation status of these
T cells is impaired. To test this, we assessed the activation
capacity of CD4+ and CD8+ T cells upon stimulation with anti-
CD3/anti-CD28 [23]. No differences in the expression of T cell
activation markers like CD44 and CD69 (Figure 4a,b) or CD25
and CD62L (data not shown) were observed between CD4+ and
CD8+ T cells fromMdr1a/1b2/2 and wild-type mice after anti-
CD3/anti-CD28 stimulation. However, anti-CD3/anti-CD28
stimulation of Mdr1a/1b 2/2 lymph node cells resulted in a
reduced release of the inflammatory cytokines TNF-a and IFN-c
compared to wild-type cells (Figure 4c). In contrast, no
differences were observed in the production of IFN-c or TNF-
a transcripts after anti-CD3/anti-CD28 stimulation between
wild-type and Mdr1a/1b2/2 lymph node cells (Figure 4d),
which correlated with no differences in intracellular IFN-c levels
in CD4+ T cells (Figure 4e) or CD8+ T cells (Figure 4f). Together,
these results indicate that P-gp is involved in the cellular
extrusion of inflammatory cytokines from lymph node cells but
not its cellular production. Moreover, P-gp does not affect the
ability of T cells to become activated, pointing to a distinct
mechanism during EAE pathology. As DCs are crucial mediators
of immune responses by regulating specific T cell responses [7],
P-gp may perform its immunomodulatory function predomi-
nantly on DCs during DC-induced T cell responses.
Figure 1. Reduced clinical signs in Mdr1a/1b2/2 mice during acute and progressive phase of EAE. (A) Clinical signs of EAE induced by
immunization of wild-type (WT) and Mdr1a/1b2/2 mice with rMOG (1–125) showing mean clinical scores (+/2 SEM) of two independent
experiments (*p,0.002 Mann-Whitney, n = 23 mice per group). (B) Mean total EAE score per WT or Mdr1a/1b 2/2 mouse. *p,0.05.
doi:10.1371/journal.pone.0008212.g001
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Specific P-gp Blockade Inhibits T Cell Proliferation during
DC-T Cell Interactions
To determine the exact role of P-gp during antigen presentation
and DC-induced T cell responses, we investigated DC-induced
proliferation of ovalbumin-specific CD8+ (OTI) and CD4+ (OTII)
T cells during P-gp blockade. CD4+ and CD8+ T cell proliferation
to OVA-loaded BMDCs was strikingly decreased in the presence
of a specific in vitro P-gp inhibitor (reversin 121; 200 nM; [24])
compared to its vehicle (Figure 5a,b). Secretion of IFN-c and
TNF-a (Th1 cytokines) was significantly decreased during P-gp
inhibited T cell proliferation on different time points (5c–f).
Notably, fixation of BMDCs showed no effect of P-gp inhibition
on CD4+ and CD8+ T cell proliferation (Figure 5g,h) or on Th1
cytokine secretion (Figure 5i–l). These results strongly suggest that
P-gp on T cells and DCs is required for secretion of inflammatory
cytokines like IFN-c and TNF-a, thereby influencing specific T
cell responses. However, as fixation of DCs prevented the P-gp
inhibitory effect during T cell proliferation, it is likely that P-gp
may exert its dominant role on DCs during immune responses.
Impaired DC Maturation in Mdr1a/1b 2/2 Mice
During pathogenic immune responses like EAE, DCs undergo
maturation upon capture and presentation of antigens to T cells in
lymphoid organs and in perivascular spaces surrounding the
cerebral vessels [25]. In Mdr1a/1b2/2 mice we observed a
decreased brain infiltration of T cells and an impaired T cell
response during EAE compared to wild-type animals (Figure 1–3).
To assess whether this was due to diminished DC maturation, we
generated BMDCs from Mdr1a/1b2/2 and wild-type mice and
stimulated them with lipopolysaccharide (LPS). Unstimulated
BMDCs from Mdr1a/1b2/2 mice displayed a more immature
DC phenotype than wild-type mice (Figure 6a) as determined by a
lower level of expression of co-stimulatory molecules CD40,
CD80, CD86 and MHCII on CD11c+ DCs (6b–e). Stimulation
with LPS resulted in a strongly decreased DC maturation in
mdr1a/1b2/2 cells compared to wild-type CD11c+ DCs
(Figure 6a–e). Various cytokines are known to be involved in
DC maturation processes and as P-gp may be involved in the
cellular extrusion of various cytokines like IFN-c [14,16], we
therefore hypothesize that the decreased maturation ability of
Mdr1a/1b 2/2 DCs is due to lower efflux of various cytokines
during DC maturation. Addition of exogenous TNF-a and IFN-c
together enhanced DC maturation and completely restored the
effect of blocking P-gp after LPS addition (Figure 6f–i), whereas
addition of these cytokines separately did not affect DC
maturation (data not shown). These data strongly suggest that P-
gp is crucial in DC function by controlling DC maturation and
subsequent T cell activation through cytokine secretion.
Discussion
Here, we demonstrate a novel in vivo physiological role for P-gp
as a key regulator of immune responses by controlling DC
maturation and subsequent DC-induced T cell responses. We here
show that P-gp knockout mice (Mdr1a/1b2/2) displayed
reduced clinical signs of EAE compared to wild-type animals.
Observed differences were associated with decreased brain
inflammation, CNS demyelination and an overall reduced T cell
response in Mdr1a/1b2/2 animals during disease.
Interestingly, we observed reduced infiltration of CD3+ T cells
into the brains of Mdr1a/1b2/2 EAE lesions, which correlated
with diminished clinical signs of EAE and an impaired T cell
response in Mdr1a/1b2/2 mice compared to wild-type mice.
EAE is a T cell–mediated CNS autoimmune disease widely used
as an animal model of MS, sharing its clinical, immunological and
pathological characteristics [5]. Like MS, EAE is originally
thought to be a CD4+ T cell mediated disease, although evidence
is emerging for a crucial role for CD8+ T cells [26]. Notably,
lymph node cells from rMOG-immunized Mdr1a/1b2/2 mice
showed significantly impaired MOG specific T cell proliferation
during EAE compared to wild-type animals, whereas a polyclonal
stimuli like PMA/ionomycin showed no significant differences
(unpublished data). Diminished proliferation coincided with
decreased Th1 and Th2, but not Th17 cytokine levels. These
results suggest that P-gp is involved in Th1 and Th2 responses
during EAE and point to an overall impaired T cell response in
Mdr1a/1b2/2 animals during EAE.
Reduced clinical signs in Mdr1a/1b 2/2 mice during EAE
may be caused by an altered immune response to myelin proteins
in these animals. During the acute and progressive phase of EAE,
we observed less brain infiltrating T cells in Mdr1a/1b 2/2 EAE
lesions. These results strongly imply that the ability of Mdr1a/
1b 2/2 T cells to become activated during immune responses is
impaired. However, anti-CD3/anti-CD28 stimulation of T cells
from Mdr1a/1b 2/2 displayed a normal activation capacity,
indicating that P-gp on T cells is not required for T cell activation
responses, which has previously been suggested for Mdr1a
encoded P-gp [27]. Interestingly, anti-CD3/anti-CD28 stimula-
tion of Mdr1a/1b 2/2 lymph node cells resulted in a reduced
release of the inflammatory cytokines TNF-a and IFN-c compared
to wild-type cells, whereas the level of intracellular cytokines or
transcripts remained unaffected. These results strongly indicate
that P-gp mediates the cellular extrusion of inflammatory cytokines
from lymph node cells but not its cellular production. As P-gp does
not affect the ability of T cells to become activated, the observed
differences in T cell responses during EAE may be initiated by P-
gp on DCs, as these cells are crucial mediators in regulating T cell
responses [7]. P-gp is expressed on both mouse and human T cells
and DCs [14,20,28] and is upregulated during DC maturation
[21]. We here demonstrate that blocking P-gp during DC-induced
T cell activation prevented specific CD4+ and CD8+ T cell
proliferation, which was accompanied by reduced secretion of
proinflammatory cytokines TNF-a and IFN-c. Notably, fixation of
DCs restored the inhibitory effect of P-gp during CD4+ and CD8+
T cell proliferation, demonstrating a crucial role for P-gp on DCs
for T cell activation via cytokine secretion. P-gp has previously
Table 1. Clinical characteristics of EAE in WT and mdr1a/1b 2/2 mice.
Mice (n) Incidence Day of onset (+/2 SD) Survival Maximal score (+/2 SEM) Maximal score day 29 (+/2SEM)
WT (23) 23/23 13.0 (+/20.4) 22/23 3.1 (+/20.06) 2.2 (+/20.04)
Mdr1a/1b 2/2 (23) 21/23 13.8 (+/20.3) 23/23 2.6 (+/20.07) 1.6 (+/20.05)*
*p,0.05 compared to WT mice.
doi:10.1371/journal.pone.0008212.t001
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Figure 2. Decreased brain inflammation in Mdr1a/1b2/2 EAE lesions. Brains were isolated from EAE mice on day 15 (A–D) and day 29 (E–H)
after immunization and the cerebellum white matter was analyzed for the infiltration of CD45+ mac1+ macrophages (green; A,B,E,F) or CD45+ CD3+ T
cells (green; C,D,G,H) and laminin positive (red) basement membranes around vessels in WT (left panel) or Mdr1a/1b2/2 (right panel) mice. Images
represent representative tissues from 4 mice per group. Magnification 2006.
doi:10.1371/journal.pone.0008212.g002
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Figure 3. Impaired Th1 and Th2 response in Mdr1a/1b2/2mice during EAE. T cell proliferation in lymph node cells isolated from wild-type
(WT) and Mdr1a/1b2/2 mice was assessed upon re-stimulation with different concentrations of rMOG (1–125) on day 15 (A) or day 29 (B) of EAE.
Supernatants from T cell proliferation assays upon re-stimulation with 10 mg/ml rMOG (1–125) were harvested and the production of the Th1
cytokines IFN-c (C,D) or TNF-a (E,F) and the Th2 cytokines IL-10 (G,H) or IL-5 (I,J) was measured on different time points (48, 72 and 96 hr).
Experiments were performed in triplicate using 4 mice per group and were presented as the mean +/2 SEM. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0008212.g003
P-gp Regulates DC Function
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been reported to be involved either directly or indirectly in the
extrusion of proinflammatory cytokines like IFN-c from T cells
[16], and IL-12 from DCs [14,21]. Autocrine IL-12 is necessary
for IFN-gamma production by DCs and the production of IL-12
during DC-induced T cell responses can influence DC induction
of a Th1 or Th2 immune response [29], which in turn may be
responsible for the observed reduced levels of IFN-c in our assays.
However, in our studies levels of IL-12 were too low to detect
differences between Mdr1a/1b 2/2 and wild-type animals
(unpublished results). Together, these results imply an important
role for P-gp in DC function and subsequent DC-induced T cell
responses through regulation of cytokine excretion.
The maturation status of DCs is a key determinant of how the
immune response will evolve as it determines specific T cell
responses [9]. We here show that DCs that lack P-gp function,
either genetically or pharmacologically, have decreased levels of
maturation, as determined by the expression of co-stimulatory
molecules like CD40, CD80, CD86 and MHC class II antigens on
CD11c+ DCs. Reduced DC maturation in Mdr1a/1b 2/2
animals can contribute to the impaired immune response observed
Figure 4. P-gp does not affect polyclonal T cell activation. Lymph node cells isolated from WT and Mdr1a/1b2/2 mice were stimulated with
anti-CD3/anti-CD28 for 5 hr and subsequently stained for T cell activation markers CD69 (A) or CD44 (B) on live cell gated CD4+ or CD8+ T cells. After
anti-CD3/anti-CD28 stimulation, cytokine production of IFN-c, TNF-a or IL-10 was measured (C) and IFN-c and TNF-a transcripts were detected by RT-
PCR and presented as relative expression compared to GAPDH (D). Intracellular IFN-c production in CD4+ (E) or CD8+ T cells (F) was determined on
permeabilized lymph node cells after anti-CD3/anti-CD28 stimulation. Experiments were performed in triplicate using 5 mice per group and were
presented as the mean +/2 SEM. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0008212.g004
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in vivo during EAE, thereby demonstrating a pivotal role for P-gp
as an immunomodulatory molecule. Interestingly, we are the first
to show a defective DC phenotype in Mdr1a/1b2/2 mice as
determined by an impaired DC maturation capacity. We postulate
that P-gp mediates DC maturation by influencing the excretion of
proinflammatory cytokines like TNF-a and IFN-c as lower levels
of these cytokines were detected during DC-T cell interactions.
However, a controversial issue remains whether P-gp itself is
capable of transporting cytokines as suggested by some groups
[14,16,21] or that P-gp is involved in the secretion of other
relevant physiological substrates like platelet activating factor [19]
that in turn may affect cytokine secretion like IFN-c [30] as a
secondary effect. Nevertheless, addition of TNF-a and IFN-c to P-
gp deficient DCs restored their maturation capacity, highlighting
an important role for P-gp and these cytokines during DC
maturation and subsequent immune responses.
Together, we here demonstrate an impaired adaptive immunity
response in Mdr1a/1b2/2 mice in vivo, as these mice develop
reduced clinical signs of EAE. Reduced clinical signs coincided
with decreased levels of DC maturation and impaired DC-induced
T cell responses. DCs regulate Th1 and Th2 responses by the
production of various cytokines [29], and we hypothesize that P-gp
mediates DC maturation and T cell responses by influencing the
extrusion of proinflammatory cytokines like TNF-a and IFN-c,
thereby regulating immune responses. Our results indicate a novel
in vivo physiological role for P-gp during immune processes, which
may open new avenues for the treatment of various immune
mediated diseases. Based on our results, the prime target for the
treatment of MS is affecting P-gp on DCs by immunotherapy, as
DCs are ideal tools for immunotherapeutic strategies due to their
intrinsic capacity to efficiently present antigens to T cells thereby
regulating T cell responses. Interestingly, two compounds, IFN-b
and glatiramer acid (GA) that are widely used in the clinic for MS
patients have DCs as potential targets [31,32]. In conclusion, our
work highlights a new immunomodulatory role of P-glycoprotein
in adaptive immunity and reveals a new target for immunotherapy
to suppress adaptive immunity during immune responses and
neuroinflammation.
Materials and Methods
Mice
Female Mdr1a/1b2/2 and wild type (FVB) mice, 8–12-week
of age, were kindly provided by dr. Alfred Schinkel (NKI
Amsterdam). Mdr1a/1b2/2 mice showed no indications for
spontaneous colitis after extensive pathological screening and
displayed no differences in BBB permeability for non-P-gp
substrates [33]. Female C57BL/6-J or C57BL/6-N mice, 7–12
weeks of age, were obtained from Charles River (L’Arbresle,
France) or Janvier (France), respectively. OT-I and OT-II mice
were bred at the animal facility of the VU University Medical
Center (Amsterdam, The Netherlands). OT-I and OT-II mice
have transgenic Va2Vb5 T cell receptors that recognize the
OVA257–264 peptide in the context of H2-K
b and the OVA323–339
peptide in the context of I-Ab, respectively. All mice were kept
under specific pathogen-free conditions and used in accordance
with local animal experimentation guidelines.
Induction of Chronic EAE in Mdr1a/1b and Wild-Type
(FVB) Mice
EAE was induced in 8–12-week-old female Mdr1a/1b2/2 and
wild type (FVB) mice via subcutaneous immunization with 200 mg
recombinant myelin oligodendrocyte glycoprotein (rMOG 1–125;
synthesized as described [34]) in an emulsion mixed (volume ratio
1:1) with Complete Freund’s Adjuvant (CFA; Difco Laboratories)
containing 500 mg of heat-killed Mycobacterium tuberculosis H37Ra
(MBT; Difco). Control (CFA) animals were injected with saline
mixed with CFA containing 500 mg of heat-killed MBT. All
animals were additionally intraperitoneally (i.p.) injected with
Figure 5. P-gp is necessary for CD4+ and CD8+ T cell
proliferation. Bone marrow derived DCs (BMDCs) were coated with
MHC class I OVA257–264 peptide or MHC class II OVA323–339 peptide and
were used as stimulators for T cell proliferation. For this, titrated BMDCs
were cultured with purified OT-I (A) or OT-II (B) in the presence or
absence of the P-gp inhibitor reversin 121 (10 mM) or its vehicle DMSO
(0.1%). Cytokine production of IFN-c (C,D) or TNF-a (E,F) was measured
after 48 hr of co-culture. OVA peptide coated BMDCs were fixated with
0.1% PFA for 10 minutes after which OT-I (G) or OT-II (H) proliferation
was measured together with IFN-c (I,J) or TNF-a (K,L) production after
48 hr of co-culture. Representative results are depicted as the mean
+/2 SEM from three independent experiments performed in triplo.
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0008212.g005
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200 ng pertussis toxin derived from Bordetella pertussis (Sigma,
Zwijndrecht, The Netherlands) in 200 mL saline at the time of, and
after 24 hr following immunization. Mice (n = 23 per group) were
examined daily for clinical signs of EAE and were scored as
followed: 0, no disease; 1, limp tail; 2, hindlimb weakness; 3,
complete hindlimb paralysis; 4, hindlimb paralysis plus forelimb
paralysis; and 5, moribund or dead. Mice were killed at day 15 or
29 using O2/CO2. All experimental procedures were reviewed
Figure 6. P-gp mediates DC maturation via IFN-c and TNF-a secretion. (A) DC maturation of BMDCs isolated from WT (shaded histogram) or
Mdr1a/1b2/2 (open histogram) mice were determined by the expression of CD40, CD80, CD86 or MHCII on live cell gated and CD11c+ cells in the
presence or absence of LPS. Quantification of DC maturation of CD11c+ cells positive for CD40 (B), CD80 (C), CD86 (D) and MHCII (E). Recombinant
IFN-c or TNF-a (5 ng/ml) was added to BMDCs derived from C57Bl/6 mice cultured in the presence or absence of LPS, the P-gp inhibitor reversin 121
(10 mM) or its vehicle DMSO (0.1%). Experiments were performed in triplicate using 5 mice per group (A–E) or three independent experiments (F–I)
and were presented as the mean +/2 SEM. *p,0.05.
doi:10.1371/journal.pone.0008212.g006
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and approved by the Ethical Committee for Animal Experi-
ments of the VU University Medical Center (Amsterdam, The
Netherlands)
Histology and Immunohistochemistry
Four animals per group were sacrificed for T cell proliferation
and histological examination on the peak of disease (day 15) and
at the end of disease (day 29). Brains of sacrificed animals were
dissected, snap-frozen in liquid nitrogen, and stored at 280uC.
Kluver-Barrera (Luxol fast blue/cresyl violet) staining was
performed on cryostat sections (5 mm) as described (Breij et al,
2005). For immunohistochemistry, cryostat sections were fixed in
ice-cold acetone for 10 minutes and blocked with normal mouse
serum (NMS) prior to antibody staining. Immunofluorescence
staining was performed in PBS, supplemented with 0.1% (wt/vol)
bovine serum albumin (BSA) as previously described [35,36] and
all antibodies are described in Table S1. Monoclonal conjugated
antibodies for CD3, CD4 or CD8 were used to detect infil-
trated T cells and monocyte infiltration was detected with the
conjugated monocyte/macrophage marker mac-1. Cerebral
blood vessels were detected with an unconjugated polyclonal
antibody directed against laminin and binding was revealed using
goat anti-rabbit Alexa FluorH 546 (Invitrogen). Sections were
rinsed, dried, and mounted in Vectamount (Vector Laboratories).
Immunofluorescent sections were enclosed in Vinol (Air Prod-
ucts, Allentown, USA) supplemented with DAPI (Invitrogen) and
analyzed on a Leica DM6000 fluorescence microscope (Leica
Microsystems, Heidelberg, Germany), equipped with LAS AF
(Leica) software.
Immune Cell Activation Assays and Cytokine Analysis
Lymph node cells (16106 or 0,56106 cells/well respectively)
were isolated as described [37] and were cultured in flat-bottomed,
96-well plates in media (IMDM supplemented with 2 mM L-
glutamine, 100 U ml-1 penicillin, 0.1 mg ml-1 streptomycin,
0.5 M 2-mercaptoethanol and 10% fetal calf serum). Cells were
subsequently stimulated with rMOG (1–125) in various concen-
trations (3–30 mg/ml). As a positive control, cells were stimulated
with PMA (20 ng/ml; Sigma)/ionomycin (500 ng/ml; Sigma). To
assess proliferation rate, cultures were pulsed with [3H]-thymidine
(1 mCi/well) after 48 h of culture and harvested 18 h later onto
filter paper. The counts per minute (c.p.m.) of incorporated [3H]-
thymidine were measured on a Wallac-LKB Betaplate 1205 liquid
scintillation counter. Cytokines were measured in the supernatants
of cultured cells using a mouse inflammation CBA kit (BD
Pharmingen). Supernatants were taken at four different time
points after stimulation (24, 48, 72 and 96 hrs). For lymph node
activation assays, cells were pooled from four animals per group
and triplicate wells plated.
In Vitro Ag-Presentation Assays
Bone marrow derived DCs (BMDCs) were isolated and cultured
in the presence of GM-CSF as described previously [38]. BMDCs
were coated with 1 mg/ml MHC class I-restricted OVA257–264
peptide or 10 mg/ml MHC class II-restricted OVA323–339 peptide
for 30 minutes and washed three times and control or fixated (PFA
0.1%, 10 min) BMDCs used as stimulators for naive T cells in a
[3H]-thymidine incorporation assay in the presence or absence of
the in vitro P-gp inhibitor reversin 121 (10 mM; Alexis) or its
vehicle DMSO (0.1%). T cells were obtained from spleen and
lymph nodes from OT-I and OT-II transgenic mice. CD8+ T cells
and CD4+ T cells were purified by negative depletion using bead-
based T cell isolation kits (Dynal Biotec ASA, Oslo, Norway) from
OT-I and OT-II mice, respectively, following manufacturer’s
protocols. Purity of T cell preparations was between 80 and 90%.
After 48 h incubation in a CO2 incubator, plates were pulsed with
1 mCi/well of [3H]-thymidine. After additional 16 h of incubation,
[3H]-thymidine incorporation was measured on a Wallac-LKB
Betaplate 1205 liquid scintillation counter. Experiments were
performed in triplicate and presented as the mean +/2 SEM.
T Cell Activation
Lymph node cells were stimulated with anti-CD3 (10 ug/ml)/
anti-CD28 (2 ug/ml) for 5 hr. Cell surface expression of CD44,
CD69, CD62L, CD25 was determined by gating on CD4+ or
CD8+ T cells (Table S1). All staining procedures were performed
using ice-cold PBS containing 1% BSA and 0.02% Na-azide.
Intracellular IFN-c expression was determined by permeabiliza-
tion and staining of cells with reagents provided in the Cytofix/
Cytoperm kit according to the manufacturer’s instructions (BD
Pharmingen). Flow cytometry was performed on a FACSCali-
burTM with the use of CELLQuestTM software (Becton Dickinson,
Franklin Lakes, NJ) with auto-fluorescent cells excluded.
BMDC Maturation
BMDC were stimulated with or without LPS in the absence or
presence of the P-gp inhibitor reversin 121 (10 mM; Alexis) or
mouse recombinant cytokines cytokines IFN-c and TNF-a (5 ng/
ml; Peprotech). After 16 hrs, cells were washed with PBS/BSA
0.1% and stained for the expression of co-stimulatory molecules
CD40, CD80, CD86 and MHCII on CD11c+ cells (Table S1).
Cells were fixed in 2% PFA and flow cytometry was performed as
described above.
RNA Isolation and Real-Time Quantitative PCR
Messenger RNA was isolated from control or stimulated (anti-
CD3/anti-CD28 see above) lymph node cells using an mRNA
capture kit (Roche) according to the manufacturer’s instructions.
cDNA was synthesized with the Reverse Transcription System kit
(Promega, USA) following manufacturer’s guidelines and RT-
PCR was performed as described previously [39]. All primer
sequences are listed in Table S2 and expression levels of transcripts
obtained with real time PCR were normalized to GAPDH
expression levels.
Statistical Analysis
EAE clinical scores for groups of mice are presented as the
mean clinical score +/2 s.e.m and statistical differences were
analyzed by the Mann-Whitney U nonparametric ranking test. All
other data were analyzed statistically by means of analysis of
variance (ANOVA) and Student-Newman-Keuls test. Statistical
significance was defined as *p,0.05, ** p,0.01, *** p,0.001.
Supporting Information
Figure S1 Decreased demyelination in mdr1a/1b2/2 EAE
lesions. Brains were isolated from non-immunized control mice (A)
or EAE mice 29 days after immunization (B,C) and the cerebellum
white matter was analyzed for demyelination using Kluver-Barrera
staining in control (A), WT (B) or mdr1a/1b2/2 (C) mice.
Arrows indicate demyelinated areas and arrowheads indicate
infiltrated leukocytes. Images represent representative tissues from
4 mice per group. Magnification 10x.
Found at: doi:10.1371/journal.pone.0008212.s001 (0.90 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0008212.s002 (0.02 MB
DOC)
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Table S2
Found at: doi:10.1371/journal.pone.0008212.s003 (0.02 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0008212.s004 (0.02 MB
DOC)
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